id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-N-3533-0040,FDA,FDA-2024-N-3533,Reference 2 - Transcript for Sept. 7 2023 Panel Meeting,Supporting & Related Material,Background Material,2026-04-20T04:00:00Z,2026,4,,,2026-04-20T20:26:51Z,,0,0,09000064b9285e39
FDA-2024-N-3533-0034,FDA,FDA-2024-N-3533,Final Order Reference 1 - Meeting Transcript for Sept. 7 2023 Panel Meeting,Supporting & Related Material,Background Material,2026-04-20T04:00:00Z,2026,4,,,2026-04-20T20:25:54Z,,0,0,09000064b9282d3f
FDA-2024-N-3533-0042,FDA,FDA-2024-N-3533,Reference 4 - CDC Clinical Testing and Diagnosis for Hepatitis B,Supporting & Related Material,Background Material,2026-04-20T04:00:00Z,2026,4,,,2026-04-20T20:27:00Z,,0,0,09000064b9285e3b
FDA-2024-N-3533-0036,FDA,FDA-2024-N-3533,Final Order Reference 3 - CDC Clinical Testing and Diagnosis for Hepatitis B,Supporting & Related Material,Background Material,2026-04-20T04:00:00Z,2026,4,,,2026-04-20T20:26:02Z,,0,0,09000064b9285e35
FDA-2024-N-3533-0038,FDA,FDA-2024-N-3533,List of References_FDA-2024-N-3533,Supporting & Related Material,Background Material,2026-04-20T04:00:00Z,2026,4,,,2026-04-20T20:26:41Z,,0,0,09000064b9285e37
FDA-2024-N-3533-0035,FDA,FDA-2024-N-3533,Final Order Reference 2 - Summary Minutes for Sept. 7 2023 Panel Meeting,Supporting & Related Material,Background Material,2026-04-20T04:00:00Z,2026,4,,,2026-04-20T20:25:59Z,,0,0,09000064b9282d40
FDA-2024-N-3533-0037,FDA,FDA-2024-N-3533,Final Order Reference 4 - P190034 Summary of Safety and Effectiveness,Supporting & Related Material,Background Material,2026-04-20T04:00:00Z,2026,4,,,2026-04-20T20:26:06Z,,0,0,09000064b9285e36
FDA-2024-N-3533-0039,FDA,FDA-2024-N-3533,Reference 1 - Summary Minutes Sept. 7 2023 Panel Meeting,Supporting & Related Material,Background Material,2026-04-20T04:00:00Z,2026,4,,,2026-04-20T20:26:46Z,,0,0,09000064b9285e38
FDA-2024-N-3533-0041,FDA,FDA-2024-N-3533,Reference 3 - Terrault N.A. Update on Prevention Diagnosis and Treatment of Chronic Hepatitis B,Supporting & Related Material,Background Material,2026-04-20T04:00:00Z,2026,4,,,2026-04-20T20:26:57Z,,0,0,09000064b9285e3a
FDA-2024-N-3533-0033,FDA,FDA-2024-N-3533,List of Final Order References_FDA-2024-N-3533,Supporting & Related Material,Background Material,2026-04-20T04:00:00Z,2026,4,,,2026-04-20T20:25:47Z,,0,0,09000064b9282d3e
FDA-2024-N-3533-0032,FDA,FDA-2024-N-3533,"Microbiology Devices; Reclassification of Antigen, Antibody, and Nucleic Acid-Based Hepatitis B Virus Assay Devices",Rule,Final Rule,2025-09-18T04:00:00Z,2025,9,2025-09-18T04:00:00Z,,2025-09-18T18:53:51Z,2025-18082,0,0,09000064b8fb1032
FDA-2024-N-3533-0001,FDA,FDA-2024-N-3533,"Microbiology Devices; Reclassification of Antigen, Antibody, and Nucleic Acid-Based Hepatitis B Virus Assay Devices",Proposed Rule,Request for Comment,2024-09-25T04:00:00Z,2024,9,2024-09-25T04:00:00Z,2024-11-26T04:59:59Z,2024-11-26T02:00:30Z,2024-21932,0,0,0900006486782c1a